Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma
Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug—a CTLA-4 ...
Apr 8, 2022
0
8